Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Post-transplant CT for GVHD Prediction
NCT02117115Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2014
- Primary completion
- Oct 2014
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial, sponsored by Washington University School of Medicine. Primary endpoints: Incidence of contrast related nephropathy at 72 hours and Incidence of contrast allergic reaction at 4 hours. Started Jun 2014; status: completed.
Beyond the preview
Go deeper on NCT02117115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02117115.